Cargando…

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease

OBJECTIVES: Ustekinumab (UST) optimization strategies, including shortening intervals and intravenous reinduction, should be administered to patients with partial or loss of respond. Evidence comparing these types of optimization treatments is limited. We evaluated the efficacy and safety of weight-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Jiayin, Peng, Xiang, Zhong, Yingkui, Su, Tao, Bihi, Adam, Zhao, Junzhang, Liu, Tao, Wang, Wei, Hu, Pinjin, Zhang, Min, Zhi, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406215/ https://www.ncbi.nlm.nih.gov/pubmed/37554510 http://dx.doi.org/10.3389/fmed.2023.1105981

Ejemplares similares

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn’s Disease: A Retrospective Real-World Analysis
por: Yao, Jiayin, et al.
Publicado: (2023)

A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
por: Bennett, Audrey, et al.
Publicado: (2020)

Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study
por: Yao, Jia-yin, et al.
Publicado: (2021)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
por: Xiao, Teresa L., et al.
Publicado: (2022)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
por: Cohen, Alexandra, et al.
Publicado: (2021)

Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
por: Hoffmann, Peter, et al.
Publicado: (2019)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
por: Saman, Sadik, et al.
Publicado: (2019)

Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy
por: Scribano, Maria Lia, et al.
Publicado: (2022)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn’s Disease Patients: A Case Report and Review of the Literature
por: Thomas, Pepijn W A, et al.
Publicado: (2020)

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab
por: Lim, Yizhe, et al.
Publicado: (2021)

Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
por: Lee, Scott D., et al.
Publicado: (2016)

Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
por: Lee, Scott David, et al.
Publicado: (2022)

Successful Treatment of Refractory Autoimmune Enteropathy With Ustekinumab
por: Scheid, Johannes F., et al.
Publicado: (2021)

Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
por: Perez Del Nogal, Genesis, et al.
Publicado: (2022)

Polymorphisms of the TNF Gene and Three Susceptibility Loci Are Associated with Crohn’s Disease and Perianal Fistula Crohn’s Disease: A Study among the Han Population from South China
por: Zhang, Min, et al.
Publicado: (2019)

Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn’s Disease Patients
por: Doherty, Matthew K., et al.
Publicado: (2018)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease
por: Cohen, Barrie, et al.
Publicado: (2021)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
por: Andres, Brendan, et al.
Publicado: (2022)

Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
por: Hejna, M., et al.
Publicado: (1998)

The Role of Recombination Activating Gene (RAG) Reinduction in Thymocyte Development in Vivo
por: Yannoutsos, Nikos, et al.
Publicado: (2001)

Body Mass Index Is a Marker of Nutrition Preparation Sufficiency Before Surgery for Crohn's Disease From the Perspective of Intra-Abdominal Septic Complications: A Retrospective Cohort Study
por: Zhang, Min, et al.
Publicado: (2015)

Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease
por: Tuskey, Anne, et al.
Publicado: (2014)

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
por: Deepak, Parakkal, et al.
Publicado: (2016)

Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn's Disease
por: Mishra, Avantika, et al.
Publicado: (2018)

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab
por: Doornekamp, Laura, et al.
Publicado: (2020)

Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Disease
por: Globig, Anna-Maria, et al.
Publicado: (2020)

An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
por: Chien, Tzu Hsiang, et al.
Publicado: (2021)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4pe24t65lires6h3dbmhejqj0j